Anixa Biosciences Inc. (ANIX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Anixa Biosciences Inc. (NASDAQ: ANIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.12 (-5.45% 1D, market cap $114.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANIX ranks #777 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLSA (Tiziana Life Sciences Ltd.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $115.1M) and NRXP (NRX Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $115.2M). Among the 5-stock peer group, ANIX leads on earnings multiple (N/A) while ANIX leads on capital efficiency (-35.0% ROIC).
Per ANIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0000715446), Anixa Biosciences Inc. generated $0 in revenue (-100.0% YoY), -$10.9M in net income, and -$7.2M in free cash flow against $15.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 56.3 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ANIX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.97) and Max Pain ($3.28) forces dealer call-delta covering toward $5.73.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Anixa Biosciences Inc. (ANIX) dropped -5.45% to $3.12, trading at 25% of its 52-week range ($2.32 – $5.46). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
- SEC Filing
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth cohort in its ongoin
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ANIX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ANIX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Anixa Biosciences Inc. (ANIX) ranks #777 by composite RQD confidence (32/100, grade E) and #642 by equity capitalization ($114.7M). Within this direct 5-issuer industry benchmark cohort, ANIX leads on earnings valuation at N/A trailing P/E, while ANIX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TLSA currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with ANIX at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANIX
ACTIVE
Anixa Biosciences Inc. | E | 32/100 | — | — | -35.0% | -5.45% | $114.7M | Benchmark Subject |
| TLSA Tiziana Life Sciences Ltd. | D+ | 55/100 | — | — | — | -11.57% | $115.1M | /tlsa-vs-anix → |
| NRXP NRX Pharmaceuticals Inc. | D- | 36/100 | — | 58.8% | -35.0% | -14.66% | $115.2M | /nrxp-vs-anix → |
| CLLS Cellectis S.A. | D | 49/100 | — | — | — | -7.69% | $117.6M | /clls-vs-anix → |
| EQ Equillium Inc. | D- | 42/100 | — | — | -35.0% | -3.52% | $111.3M | /eq-vs-anix → |
In its most recent audited fiscal period (FY2025, filed 2025-10-31), Anixa Biosciences Inc. (ANIX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $210.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$10.9M, operating cash flow of -$7.2M, and free cash flow of -$7.2M (+2.2% YoY). On the balance sheet, ANIX closed FY2025 with $15.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-10-31 | $0 | -$10.9M | -$7.2M | -$7.2M | $15.2M | — |
| FY2024 (FY) | 2024-10-31 | $210.0K | -$12.6M | -$7.3M | -$7.3M | $18.9M | — |
| FY2023 (FY) | 2023-10-31 | $210.0K | -$9.8M | -$6.2M | -$6.2M | — | — |
As of 2026-11-02, Anixa Biosciences Inc. (NASDAQ: ANIX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.12 (-5.45% 1D, market cap $114.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ANIX ranks #777 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TLSA (Tiziana Life Sciences Ltd.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $115.1M) and NRXP (NRX Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $115.2M). Among the 5-stock peer group, ANIX leads on earnings multiple (N/A) while ANIX leads on capital efficiency (-35.0% ROIC).
Per ANIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0000715446), Anixa Biosciences Inc. generated $0 in revenue (-100.0% YoY), -$10.9M in net income, and -$7.2M in free cash flow against $15.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ANIX last traded at $3.12 (-5.45% on volume of 140,662 shares), positioning the stock +5.05% above its 50-day simple moving average ($2.97) and +5.05% above its 200-day simple moving average ($2.97). Across its 52-week range of $2.32 to $5.46, ANIX sits at the 25.5% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.73 to $3.51).
Why ANIX Stock dropped -5.45% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD rating assigns ANIX a score of 32 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the scores are:
Investor implications: the upside case depends on a clinical or commercial inflection that the reported financials do not yet show. The valuation tradeoff is that the market capitalization of $114.7M is set against negative operating income and negative free cash flow, so the equity carries funding and dilution risk. The rating's overall verdict is a strong negative signal on forensic and cash-generation grounds.
Anixa Biosciences Inc. (ANIX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it is a publicly traded biotechnology company with a market capitalization of $0.1B. Per the recent news wire, the company's stated focus includes CAR-T therapy for ovarian cancer and a breast cancer vaccine. The source data does not describe its customers or revenue model in detail; reported revenue is $0.0M for FY 2025 per the SEC financials.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-11.7M | $-10.9M | N/A | $-7.2M | $1.5M | N/A |
| FY 2024 | $0.2M | $-13.8M | $-12.6M | N/A | $-7.3M | $1.1M | N/A |
| FY 2023 | $0.2M | $-11.0M | $-9.8M | N/A | $-6.2M | N/A | N/A |
Per the SEC financials, the company reported operating losses in each period shown, with revenue falling to $0.0M in FY 2025. Gross, operating, and net margins are each listed as 0% in the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash was $1.5M at FY 2025 against a free cash flow outflow of $-7.2M.
Per the recent news wire, the catalysts include:
All news items are tagged YELLOW with the impact label MARKET WIRE. Risk watch items: the cash balance of $1.5M is small relative to the FY 2025 free cash outflow of $-7.2M; the shares are down -5.45% on the day; and the stock trades near the low end of its 52-week range. The Butterfly Supply-Chain Graph contains no supply-chain links and no proprietary signals.
Supply chain: NONE. Butterfly links: none. Proprietary signals: none. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be mapped from the source data. A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from partners, suppliers, or customers. Watch items drawn from the other sections: dependence on external funding given negative free cash flow, and the sensitivity of clinical-stage sentiment to news flow described above.
Real-time company headlines, analyst actions, and sector developments for Anixa Biosciences Inc. (ANIX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Anixa Biosciences Inc. (ANIX) market action, institutional positioning, and fundamental catalysts.
Welcome to the ANIX (Anixa Biosciences Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ANIX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Anixa Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ANIX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.12 (52-wk range $2.32 - $5.46), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).